HIMS

Hims & Hers Health reported 38% revenue growth to $753 million and raised its full-year 2026 outlook to $3.1-$3.3 billion in revenue and $275-$325 million in adjusted EBITDA, driven partly by the Eucalyptus acquisition.

Hims & Hers Health stock fell 6.7% to $28.39 on Wednesday, September 23, underperforming the broader market, as investors weighed mounting legal and financial pressures. The stock has lost over 12% year-to-date and more

Hims & Hers Health faces an FTC complaint and multiple securities class-action lawsuits by mid-2026, alleging improper sharing of sensitive health data with third-party advertising platforms and misleading billing practi

JPMorgan resumed coverage of Hims & Hers Health at Neutral with a December 2027 price target of $32, implying roughly 17% upside from the Sept. 10 close, as analyst Bryan Smilek (who previously rated the shares Overweigh

Median compensation for executives with 'technology' in their title surged 45.4% to $2.6 million in the most recent fiscal year, far outpacing other C-suite roles, according to data from C-suite Comp. The increase in dol

Hims & Hers Health shares fell 7.7% in the month following its Q2 2026 earnings report, which showed an adjusted loss per share of 10 cents—wider than the 7-cent consensus estimate and a reversal from a year-ago profit o

Hims & Hers Health shares fell 4% to $28.44 on Tuesday after the FDA issued a warning about unapproved GLP-1 weight-loss drugs, overshadowing the company’s expansion into Australia. The FDA reiterated that unapproved GLP

Hims & Hers Health stock fell 8.9% to near $28.84, about 54% below its 52-week high. While the stock typically recovers from market shocks within months, its deepest historical drawdown of 87% (2021-2022) exceeds any sho